Group items tagged

At the Atlas Spinal Clinic our fundamental concern is getting to the root cause of health problems, rather than treating symptoms. Our Atlas Orthogonal (AO) work centers on what we call the pillar of life, the spinal column, a vital part of the body that directly affects its whole wellbeing.

The blood-forming stem cells used for cancer therapy are called hematopoietic stem cells. They constitute less than one in 1,00,000 bone marrow cells. They look like small lymphocytes (a type of white blood cell in the vertebrate immune system) and cannot be easily distinguished. These cells are capable of self-renewal as well as production of progenitor cells, which differentiate into mature blood cells. Bone marrow, peripheral blood (the blood returning to the heart) and cord blood (obtained from the umbilical cord at birth) are three good sources of hematopoietic stem cells.

xamthone plus sangat bagus mengobati tumor dengan baik dan ampuh karena Pengobatan herbal untuk tumor xamthone plus jus kulit manggis sangat luar biasa dalam mengobati penyakit tumor ,dan sudah banyak orang yang merasakan kesembuhan dengan Pengobatan herbal untuk tumor dan jangan ragu khasiat nya , Pengobatan herbal untuk tumor Ayo obati penyakit anda sebelum terlambat karena didunia ini hidup cuma sekali dan raih lah kebahagiaan dengan obat herbal xamthone plus yang akan membantu menyembuhkan penyakit anda Setiap penyakit, ada obatnya.

A brain is an organ often composed of Connective tissues and nerve cells. The brain contains three important parts including breathe controlling and muscles like moving muscles and sensing like emotions breathing, memory thinking and somewhat personality.

Brain Tumor risks including surgery facts, as well as diagnosis also types either the primary tumor or secondary tumor. Treatments like MRI CT scan helping you to decide better for your health.

India has some of the top brain tumour surgery hospitals that have the most recent and advanced imaging techniques supported by connoisseurs in the field of cancer treatment. Brain tumour is marked by an abnormal growth of cells in the brain, which end up forming a mass of cells, lesion or a tumour.

Patients with advanced non-small cell lung cancer (NSCLC) may soon be offered a blood test to assess their treatment options, instead of having to provide a tumour sample for analysis.

Immuno-Transcriptomics firm Novigenix has received positive results from its early colon cancer detection blood test at the European Society for Medical Oncology (ESMO) 2019.

An oral drug combination by Novartis showed promise in treating a subgroup of patients suffering from a common childhood brain cancer in a trial. In the mid-stage trial, 47 per cent of the patients that were given the two drugs Tafinlar and Mekinist saw their tumours shrink, far above a rate of 11 per cent in a comparative group of participants on standard chemotherapy, the drugmaker said on Monday, June 6. The participants, aged one to 17 years, were suffering from low-grade gliomas (LGG), the most common childhood brain cancer. The trial only included those who were found to have a mutation known as BRAF V600, a genetic contributor in about 15 per cent to 20 per cent of paediatric LGG cases. Among further results of the trial with 110 participants, the median time without disease progression was 20.1 months for those given the Novartis drug combo, compared to 7.4 months on chemotherapy. The new oral treatment candidate also caused less severe side effects than burdensome chemotherapy.

After receiving approval from the National Institute for Health and Care Excellence (NICE), the NHS is preparing to roll out a new combination treatment for brain tumours in children and young people in England. Dabrafenib with trametinib would be the first ever targeted treatment for children (aged 1-17) with gliomas that have a specific genetic mutation, the health service said. The treatment, which can be taken at home, has been found to slow the progression of the disease by over threefold compared to standard chemotherapy in children with low-grade gliomas that have a BRAF V600E mutation. Clinical trials have shown that it causes fewer side-effects than chemotherapy. NICE approved the combination treatment on Wednesday 24 April. It will be available on the NHS in the coming months.